Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano have announced that their Chief Executive Officer, Vuong Trieu, will present the Deciparticle(TM) nanomedicine platform at the BIO International Convention 2026 in San Diego. The presentation will focus on the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics, a significant hurdle in drug delivery. The Deciparticle(TM) platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles, which are particularly suited for oncology and other therapeutic applications.
The companies plan to showcase development progress across multiple Deciparticle(TM) programs. Key among these is Sapu006, a polysorbate-free intravenous docetaxel formulation that is moving into Phase 1b clinical evaluation. Another program, Sapu003, is an intravenous everolimus nanomedicine currently in a global Phase 1b clinical trial. The presentation will also highlight the integration of artificial intelligence and knowledge-organization technologies into formulation development and translational oncology workflows through the PDAOAI(TM) platform. This integration aims to accelerate the development of nanomedicines by leveraging advanced data analysis and knowledge integration.
The significance of this announcement lies in the potential of the Deciparticle(TM) platform to overcome a longstanding challenge in drug development: the poor water solubility of many therapeutic compounds, which often limits their clinical use. By enabling intravenous administration of such drugs, the platform could improve their bioavailability and therapeutic index, potentially leading to more effective treatments with fewer side effects. This is particularly important in oncology, where many potent anticancer agents are highly insoluble.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy, while Sapu Nano specializes in next-generation nanomedicine platforms. The collaboration between the two companies aims to unlock the clinical potential of both established and novel therapeutics. The presentation at the BIO International Convention, a major industry event, underscores the growing interest in nanomedicine solutions for drug delivery challenges.
For more information, the full press release is available at https://ibn.fm/RUG7m. Additional updates on Oncotelic Therapeutics can be found at https://ibn.fm/OTLC.
